Navigation Links


Worcester Polytechnic Institute Team Grows Heart Tissue on Spinach Leaves

3/22/2017
Worcester, Mass. (PRWEB) March 22, 2017 Researchers face a fundamental challenge as they seek to scale up human tissue regeneration from small lab samples to full-size tissues, bones, even whole organs to implant in people to treat disease or traumatic injuries: how to establish a vascular sy... [Comments]

Ascendis Pharma A/S Reports Full Year 2016 Financial Results

3/22/2017
COPENHAGEN, Denmark , March 22, 2017  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced financial results for the full year ended December 31, 2016. "2016 was a significant year for our company as we broadened our pipeline and pursu... [Comments]

UBM and Massachusetts Medical Device Industry Council (MassMEDIC) Partner for Third Annual Massachusetts Medtech Week

3/22/2017
SANTA MONICA, Calif. , March 22, 2017  UBM and the Massachusetts Medical Device Industry Council (MassMEDIC) are proud to announce their extended partnership and the third annual Massachusetts Medtech Week. Massachusetts Medtech Week will be headlined by the 21 st Annual MassMEDIC Conference held in conjunction with UBM's BIOMEDevice Boston, taking place May 3-4... [Comments]

Leading Family Genomics Company Good Start Genetics Expands Payor Relationships to More than 130 Million Covered Lives

3/22/2017
CAMBRIDGE, Mass. , March 22, 2017 Good Start Genetics, a leading family genomics company, today announced that it has eclipsed the 130 million covered lives mark through its most recent payor addition, Blue Cross Blue Shield of Texas . With newly signed contracts nationally and others in advanced stages, the Company continues to enjoy strong payor acceptance based on the qu... [Comments]

Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017

3/22/2017
JERUSALEM , March 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron , Oramed's Chief Scientific Officer, will deliver a presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," at the... [Comments]

Doctors Pathology Service (DPS) Joins Growing Biospecimens for Research Program Offered by iSpecimen and the Delaware Health Information Network (DHIN)

3/22/2017
LEXINGTON, Mass. , March 22, 2017   iSpecimen ®, the marketplace for human biospecimen collections, today announced that Doctors Pathology Service (DPS), a full-service anatomic pathology reference lab serving the mid-Atlantic region of the United States , has joined a program offered by iSpecimen and the Delaware Health Information Network (DHIN) to make human bi... [Comments]

Chronic Kidney Disease (CKD) Drugs Market to Reach US$15.8 Billion by 2024; Rise in Geriatric Population to Create Lucrative Opportunities for Players, Says TMR

3/22/2017
ALBANY, New York , March 22, 2017 The global chronic kidney disease drugs market is largely fragmented, states a research report by Transparency Market Research (TMR). The top four players, namely Sanofi S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted for a share of only 41.4% in this market in 2015. The prominent players in this market are focusing aggressively on... [Comments]

Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care

3/22/2017
PALM BEACH, Florida , March 22, 2017 MarketNewsUpdates.com News Commentary  The traditional ways to treat pain management for various cancer conditions are being pressured as of late due to the rise of the opioid crisis. Non-narcotic pain therapy for cancer pain management has a dramatic impact on patient's quality of life as Biotech and Pharma compan... [Comments]

FACIT Announces Investment in Propellon Therapeutics

3/22/2017
TORONTO , March 22, 2017 /PRNewswire/ - FACIT announced a seed stage investment in Propellon Therapeutics (the "Company" or "Propellon"), a start-up created by FACIT focused on developing a portfolio of WDR5-targeted anti-cancer therapeutics. FACIT's investment, combined with non-dilutive capital, achieves a targeted $3.0M financing for the lead program. The seed funding enables Propellon to... [Comments]

Boston Biomedical Celebrates 10-Year Anniversary of its Founding and Announces Appointment of Patricia S. Andrews as Chief Executive Officer

3/22/2017
CAMBRIDGE, Mass. , March 22, 2017   Boston Biomedical , an industry leader in the development of next-generation cancer therapeutics designed to target cancer stemness pathways, today announced its Board of Directors has appointed Patricia S. Andrews as Chief Executive Officer, effective April 24, 2017. Ms. Andrews will succeed Chiang J. Li , M.D., FACP, who has led... [Comments]

[next]
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
Breaking Biology News(10 mins):
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
Request Info...
... available in two product models - the 5000AT+ ... is that the 6000AT+ includes a membrane desolvation ... for improved detection limits and reduced oxides. The ... of elements by 10-40 times. Note that with ...
Biology Products:
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, FL ... live events series, “Stem Cell Therapy: The Next Phase in the Evolution of Medicine.” ... Stem Cell Research and Therapy Act, Okyanos maintains a mission to help “no-option” ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... peristaltic pump with patented ReNu single-use (SU) cartridge technology. Engineered by the ... feed pumps in SU tangential flow filtration (TFF), virus filtration (VF) and ...
(Date:3/22/2017)... 22, 2017  Personal Genome Diagnostics Inc. (PGDx) ... contract with the U.S. Department of Veterans Affairs ... with the company,s new CancerSELECT ™ 125 ... pan-cancer profiling test that includes microsatellite instability status ... response to checkpoint inhibitor immunotherapies. CancerSELECT 125 will ...
(Date:3/20/2017)... , ... March 20, 2017 , ... ... pharmaceutical and biotech companies, recently announced it will debut a brand new pressure ... City. The intelliVessel is controlled by a touch screen panel and features other ...
Breaking Biology Technology: